Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)

Inclusion Criteria: * 18 years of age or older * Advanced or metastatic solid tumor malignancy * ECOG performance status of less than or equal to 1 * Life expectancy of greater than 3 months * At least 4 weeks must have elapsed between prior investigational therapy, chemotherapy, or radiotherapy, and the first dose of deforolimus * Adequate hematological, hepatic and renal function * Serum cholesterol less than or equal to 350 mg/dL and triglycerides less than or equal to 400 mg/dL * Signed informed consent * Women of childbearing potential must have a negative serum pregnancy test within 7 days of starting therapy and must use an approved contraceptive method from time of screening until 30 days after the last dose of study drug Exclusion Criteria: * Tumor location in close proximity to a major blood vessel * History of brain metastases, spinal cord compression, or carcinomatous meningitis. Primary brain tumors (for example, glioblastoma) are allowed. * New brain metastases, spinal cord compression, or leptomeningeal metastases on screening CT scan or MRI * Hemoptysis or hematemesis within 28 days prior to entering the trial * Clinical significant unexplained bleeding within 28 days prior to entering the trial * Uncontrolled hypertension * Proteinuria at screening * Clinically significant cardiovascular disease * Newly diagnosed or poorly controlled type 1 or 2 diabetes * Active infection requiring prescribed intervention * Other concurrent illness that, in the Investigator's judgement, would either compromise the patient's safety or interfere with the evaluation of the safety of the study drug * Major surgery within 28 days before trial entry, or any incompletely healed surgical incision; minor surgery or procedures within 7 days * Pregnant or breastfeeding * Known allergy to macrolide antibiotics * Known hypersensitivity to any component of bevacizumab * Concurrent treatment with medications that strongly induce or inhibit cytochrome P450 (CYP3A) * Known history of HIV sero-positivity * Any condition in the Investigator's judgement that renders the patient unable to fully understand and provide informed consent and/or comply with the protocol